Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infinity Extends R&D Collaboration With Mundipharma, Gets Another $50 Million For PI3K Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.

You may also be interested in...



Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.

Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)

Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.

Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)

Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS073099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel